Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Comment on: “Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project”

A Correction to this article was published on 20 August 2021

This article has been updated

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Graphs reproduced from Shaaban et al. (Br. J. Cancer 2020; in press), illustrating the cumulative risk of ipsilateral DCIS (left panel) and of ipsilateral invasive carcinoma (right panel) after BCS only.

Change history

References

  1. Shaaban, A. M., Hilton, B., Clements, K., Provenzano, E., Cheung, S., Wallis, M. G. et al. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. Br. J. Cancer, https://doi.org/10.1038/s41416-020-01152-5 (2020).

  2. Portolani, N., Coniglio, A., Ghidoni, S., Giovanelli, M., Benetti, A., Tiberio, G. A. et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg. 243, 229–235 (2006).

    Article  Google Scholar 

  3. Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B. et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J. Natl Cancer Inst. 103, 478–488 (2011).

    Article  Google Scholar 

  4. Donker, M., Litiere, S., Werutsky, G., Julien, J. P., Fentiman, I. S., Agresti, R. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J. Clin. Oncol. 31, 4054–4059 (2013).

    Article  Google Scholar 

  5. Warnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K. et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J. Clin. Oncol. 32, 3613–3618 (2014).

    Article  Google Scholar 

  6. Wallis, M. G., Clements, K., Kearins, O., Ball, G., Macartney, J. & Lawrence, G. M. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 106, 1611–1617 (2012).

    Article  CAS  Google Scholar 

  7. Rakovitch, E., Nofech-Mozes, S., Hanna, W., Narod, S., Thiruchelvam, D., Saskin, R. et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br. J. Cancer 106, 1160–1165 (2012).

    Article  CAS  Google Scholar 

  8. Groen, E. J., Hudecek, J., Mulder, L., van Seijen, M., Almekinders, M. M., Alexov, S. et al. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Res. Treat. 183, 759–770 (2020).

    Article  Google Scholar 

  9. Thompson, A. M., Clements, K., Cheung, S., Pinder, S. E., Lawrence, G., Sawyer, E. et al. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. Eur. J. Cancer 101, 210–219 (2018).

    Article  Google Scholar 

  10. Rudloff, U., Jacks, L. M., Goldberg, J. I., Wynveen, C. A., Brogi, E., Patil, S. et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J. Clin. Oncol. 28, 3762–3769 (2010).

    Article  Google Scholar 

  11. Van Bockstal, M. R., Agahozo, M. C., Koppert, L. B. & van Deurzen, C. H. M. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int. J. Cancer 146, 1189–1197 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Author information

Authors and Affiliations

Authors

Contributions

M.R.V.B.: writing—first draft. L.L.: writing—review and editing. C.G.: writing—review and editing.

Corresponding author

Correspondence to Mieke R. Van Bockstal.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

Data availability

Not applicable.

Competing interests

The authors declare no competing interests.

Funding information

M.R. Van Bockstal received a postdoctoral mandate (grant number 2019-089) from the not-for-profit organisation Foundation against Cancer (Brussels, Belgium), and is supported by the “Fonds dr. Gaëtan Lagneaux” of the Fondation Saint-Luc (Brussels, Belgium). C. Galant is supported by the “Fonds dr. Gaëtan Lagneaux” of the Fondation Saint-Luc (Brussels, Belgium).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: Due to an Additional Information error.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van Bockstal, M.R., Libbrecht, L. & Galant, C. Comment on: “Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project”. Br J Cancer 124, 1461–1462 (2021). https://doi.org/10.1038/s41416-021-01280-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-021-01280-6

Search

Quick links